The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.
|Date||Title and Summary||View|
|Mar 3, 2010||
PTC THERAPEUTICS AND GENZYME CORPORATION ANNOUNCE PRELIMINARY RESULTS FROM THE PHASE 2B CLINICAL TRIAL OF ATALUREN FOR NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY
|Jan 19, 2010||
PTC THERAPEUTICS ANNOUNCES ADDITIONAL STUDY OF ATALUREN IN PATIENTS WITH ADVANCED NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY